Tags

Type your tag names separated by a space and hit enter

Silymarin for HCV infection.
Antivir Ther. 2013; 18(2):141-7.AT

Abstract

Silymarin, an extract of milk thistle seeds, and silymarin-derived compounds have been considered hepatoprotective since the plant was first described in ancient times. Hepatoprotection is defined as several non-mutually exclusive biological activities including antiviral, antioxidant, anti-inflammatory and immunomodulatory functions. Despite clear evidence for silymarin-induced hepatoprotection in cell culture and animal models, evidence for beneficial effects in humans has been equivocal. This review will summarize the current state of knowledge on silymarin in the context of HCV infection. The information was collated from a recent workshop on silibinin in Germany.

Authors+Show Affiliations

Department of Laboratory Medicine, University of Washington, Seattle, WA, USA. polyak@uw.eduNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Research Support, U.S. Gov't, Non-P.H.S.
Review

Language

eng

PubMed ID

23011959

Citation

Polyak, Stephen J., et al. "Silymarin for HCV Infection." Antiviral Therapy, vol. 18, no. 2, 2013, pp. 141-7.
Polyak SJ, Oberlies NH, Pécheur EI, et al. Silymarin for HCV infection. Antivir Ther (Lond). 2013;18(2):141-7.
Polyak, S. J., Oberlies, N. H., Pécheur, E. I., Dahari, H., Ferenci, P., & Pawlotsky, J. M. (2013). Silymarin for HCV infection. Antiviral Therapy, 18(2), 141-7. https://doi.org/10.3851/IMP2402
Polyak SJ, et al. Silymarin for HCV Infection. Antivir Ther (Lond). 2013;18(2):141-7. PubMed PMID: 23011959.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Silymarin for HCV infection. AU - Polyak,Stephen J, AU - Oberlies,Nicholas H, AU - Pécheur,Eve-Isabelle, AU - Dahari,Harel, AU - Ferenci,Peter, AU - Pawlotsky,Jean-Michel, Y1 - 2012/09/25/ PY - 2012/07/11/accepted PY - 2012/9/27/entrez PY - 2012/9/27/pubmed PY - 2013/9/14/medline SP - 141 EP - 7 JF - Antiviral therapy JO - Antivir. Ther. (Lond.) VL - 18 IS - 2 N2 - Silymarin, an extract of milk thistle seeds, and silymarin-derived compounds have been considered hepatoprotective since the plant was first described in ancient times. Hepatoprotection is defined as several non-mutually exclusive biological activities including antiviral, antioxidant, anti-inflammatory and immunomodulatory functions. Despite clear evidence for silymarin-induced hepatoprotection in cell culture and animal models, evidence for beneficial effects in humans has been equivocal. This review will summarize the current state of knowledge on silymarin in the context of HCV infection. The information was collated from a recent workshop on silibinin in Germany. SN - 2040-2058 UR - https://www.unboundmedicine.com/medline/citation/23011959/Silymarin_for_HCV_infection_ L2 - https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/23011959/ DB - PRIME DP - Unbound Medicine ER -